On-Body Injector: An Administration Device for Pegfilgrastim
Linda J. Mahler, RN, ANP-C, AOCNP®; Regina DiBlasi, RN, BS, OCN®; Anielka Perez, RN, MS, OCN®; Jeannie Gaspard, RN, MS, OCN®, NEA-BC; and Dayna McCauley, PharmD, BCOP
CJON
10.1188/17.CJON.121-122
Description
Many chemotherapy regimens used today require the support of a granulocyte–colony-stimulating factor for the prevention of life-threatening neutropenia. In March 2015, a delivery method was introduced for Neulasta® (pegfilgrastim) through an on-body injector (Onpro®), which may eliminate the need for patients to return for injection after chemotherapy, increase workflow, and allow more patients to be seen. The purpose of this study was to monitor the implementation of the Onpro delivery system in an outpatient facility.